Bumpus John A
Department of Chemistry and Biochemistry, University of Northern Iowa, Cedar Falls, Iowa 50614, United States.
ACS Pharmacol Transl Sci. 2020 Oct 29;3(6):1293-1303. doi: 10.1021/acsptsci.0c00132. eCollection 2020 Dec 11.
The purpose of this analysis was to assess, from the patients' perspective, the effectiveness and relative safety of tramadol as an off-label antidepressant and to determine if patients' views and experiences are consistent with the biomedical literature. A data mining approach was used to analyze databases available at drugs.com. Tramadol was reported to be an effective or very effective antidepressant by 94.6% of patients (123/130) who provided ratings submitted to (https://www.drugs.com/comments/tramadol/for-depression.html). When compared to 34 other antidepressants in the database titled (https://www.drugs.com/condition/depression.html), for which there were ≥100 individual reviews for each drug, tramadol was rated as being the most effective (effectiveness rating = 9.1/10). Phenelzine (effectiveness rating = 8.7/10) was the only other antidepressant having ≥100 individual reviews coupled with a very high (8.0-10.0) effectiveness rating. Eleven patients reported significant symptoms of withdrawal upon cessation of tramadol, and five patients reported loss or reduction of libido as a side effect. Most (57/72, 79.2%) patients who reported a dose consumed experienced relief from depression at low therapeutic doses (25-150 mg/day). Fourteen patients reported taking this antidepressant for 5-10 years, and four patients reported taking tramadol for 10 or more years. Results demonstrated that most patients' comments and beliefs are consistent with the biomedical literature. Patients' reviews coupled with a survey of the biomedical literature indicate that at low therapeutic doses in the absence of interactions with other drugs, adult patients found tramadol to be a generally safe, effective, and fast-acting medication for relief from depression.
本分析的目的是从患者的角度评估曲马多作为非标签抗抑郁药的有效性和相对安全性，并确定患者的观点和体验是否与生物医学文献一致。采用数据挖掘方法分析drugs.com上可用的数据库。在提交至（https://www.drugs.com/comments/tramadol/for-depression.html）进行评分的患者中，94.6%（123/130）报告曲马多是一种有效或非常有效的抗抑郁药。在名为（https://www.drugs.com/condition/depression.html）的数据库中，与其他34种抗抑郁药相比，每种药物都有≥100条个人评价，曲马多被评为最有效（有效性评分为9.1/10）。苯乙肼（有效性评分为8.7/10）是唯一一种有≥100条个人评价且有效性评分非常高（8.0 - 10.0）的其他抗抑郁药。11名患者报告在停用曲马多后出现明显的戒断症状，5名患者报告性欲减退作为副作用。大多数（57/72，79.2%）报告服用剂量的患者在低治疗剂量（25 - 150毫克/天）下抑郁症状得到缓解。14名患者报告服用这种抗抑郁药5 - 10年，4名患者报告服用曲马多10年或更长时间。结果表明，大多数患者的评论和观点与生物医学文献一致。患者的评价以及对生物医学文献的调查表明，在低治疗剂量且不与其他药物相互作用的情况下，成年患者发现曲马多是一种总体安全、有效且起效快的缓解抑郁的药物。
